Opus Genetics is trading 5.19% down now at $3.65, with the decline appearing primarily linked to broader biotech weakness; no company-specific catalyst was identified for August 28, 2026.
- XBI was down 2.31% as investors reduced exposure to growth stocks amid hawkish Federal Reserve messaging.
- The company’s latest major developments—Phase 3 enrollment completion and second-quarter results—were announced earlier in August, not on August 28.